SEARCH

Current Edition

Overcoming the Challenges of Large-Scale Plasmid Production

Gene therapy involves inserting a new section of DNA into a patient’s cells, often encoding a healthy gene to replace a disease-causing copy. This DNA is delivered by viral vectors which are usually built from plasmids. Katie Roberts at OXGENE examines how processes for the design and manufacturing of AAV and lentivirus plasmids can be constructed to meet the quality, regulatory and timescale challenges of bringing a new drug to market.